Wallace Owen B. 4
4 · Fulcrum Therapeutics, Inc. · Filed Sep 14, 2020
Insider Transaction Report
Form 4
Wallace Owen B.
Chief Scientific Officer
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2020-09-14−6,350→ 75,592 totalExercise: $7.84Exp: 2029-01-21→ Common Stock (6,350 underlying) - Exercise/Conversion
Common Stock
2020-09-14$7.84/sh+6,350$49,784→ 133,438 total
Footnotes (1)
- [F1]The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022.